Other institutional investors and hedge funds also recently made changes to their positions in the company. Stansberry Asset Management LLC purchased a new stake in shares of Paratek Pharmaceuticals during the fourth quarter valued at $1,285,000. Cadence Capital Management LLC grew its holdings in shares of Paratek Pharmaceuticals by 101.2% during the fourth quarter. Cadence Capital Management LLC now owns 49,328 shares of the specialty pharmaceutical company’s stock valued at $883,000 after buying an additional 24,806 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Paratek Pharmaceuticals by 12.4% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 92,366 shares of the specialty pharmaceutical company’s stock valued at $1,654,000 after buying an additional 10,202 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new stake in shares of Paratek Pharmaceuticals during the fourth quarter valued at $221,000. Finally, Highland Capital Management LP boosted its holdings in Paratek Pharmaceuticals by 373.8% in the fourth quarter. Highland Capital Management LP now owns 227,900 shares of the specialty pharmaceutical company’s stock valued at $4,079,000 after purchasing an additional 179,800 shares during the last quarter. 74.61% of the stock is currently owned by hedge funds and other institutional investors.
Metropolitan Life Insurance Co. NY cut its stake in shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) by 46.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,135 shares of the specialty pharmaceutical company’s stock after selling 7,194 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in Paratek Pharmaceuticals were worth $146,000 as of its most recent SEC filing.
In other Paratek Pharmaceuticals news, VP Adam Woodrow sold 14,333 shares of the company’s stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $13.87, for a total value of $198,798.71. Following the completion of the transaction, the vice president now owns 62,367 shares in the company, valued at $865,030.29. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Douglas W. Pagan sold 16,291 shares of the company’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $14.22, for a total transaction of $231,658.02. Following the completion of the transaction, the chief financial officer now owns 39,570 shares of the company’s stock, valued at approximately $562,685.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 68,385 shares of company stock valued at $925,282. Insiders own 4.90% of the company’s stock.
Shares of Paratek Pharmaceuticals stock opened at $10.70 on Tuesday. The stock has a market capitalization of $333.30, a price-to-earnings ratio of -3.24 and a beta of 0.43. Paratek Pharmaceuticals, Inc. has a fifty-two week low of $10.10 and a fifty-two week high of $29.00. The company has a debt-to-equity ratio of 0.72, a current ratio of 9.56 and a quick ratio of 9.56.
Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its quarterly earnings data on Thursday, March 1st. The specialty pharmaceutical company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.03). The firm had revenue of $5.07 million during the quarter, compared to analyst estimates of $5.00 million. Paratek Pharmaceuticals had a negative return on equity of 93.16% and a negative net margin of 706.00%. sell-side analysts predict that Paratek Pharmaceuticals, Inc. will post -3.48 earnings per share for the current year.
Several equities research analysts have commented on the stock. Raymond James reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Paratek Pharmaceuticals in a report on Friday, March 2nd. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a report on Thursday, February 22nd. Leerink Swann reaffirmed an “outperform” rating on shares of Paratek Pharmaceuticals in a report on Sunday, March 4th. BidaskClub raised shares of Paratek Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, April 14th. Finally, UBS lowered shares of Paratek Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a report on Friday, March 2nd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $40.00.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Want to see what other hedge funds are holding PRTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK).